Side-by-side · Research reference

ARA 290vsCardiogen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED17/59 cited

BAnimal-MechanisticHUMAN-REVIEWED5/46 cited

ARA 290

EPO-Derived Peptide · Innate Repair Receptor Agonist

4 mgDaily doseBrines 2015 Culver 2017

28 daysPhase 2 durationCulver 2017

Non-erythropoieticSafety profileBrines 2015 Liu 2014

SQ · DailyBrines 2015 Culver 2017

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

01Mechanism of Action

Parameter

ARA 290

Cardiogen

Primary target

Innate repair receptor (EPO receptor / CD131 heterodimer)

Cardiovascular cell gene expressionKhavinson 2022

Pathway

EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Downstream effect

Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014 Culver 2017

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Feedback intact?

N/A — does not interact with hematopoietic EPO receptorLiu 2014

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

Origin

11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Antibody development

Not reported in clinical trials

—

02Dosage Protocols

Parameter

ARA 290

Cardiogen

Standard dose (Phase 2)

4 mg / dayBrines 2015 Culver 2017

Sarcoidosis SFN and diabetic neuropathy trials.

—

Frequency

Once daily

Self-administered subcutaneously.

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

Duration

28 days (Phase 2)Culver 2017

Corneal nerve improvements observed by day 28.

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

Evidence basis

Phase 2 RCTsCulver 2017 Brines 2015

64-subject sarcoidosis trial, type 2 diabetes trial.

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Route

SubcutaneousBrines 2015

Subcutaneous injection

Timing

Any time of day

No circadian dependence reported.

—

Standard dose

—

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

03Metabolic / Fat Loss Evidence

Parameter

ARA 290

Cardiogen

Primary effect

Improved metabolic control (HbA1c, fasting glucose)Brines 2015

Secondary to neuropathy treatment; direct lipolytic effects not established.

—

HbA1c

Significant reduction vs placebo

Observed in type 2 diabetes + neuropathy trial.

—

Fasting glucose

Improved in ARA 290 group

—

Body composition

Not directly quantified

Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.

—

04Side Effects & Safety

Parameter

ARA 290

Cardiogen

Injection site reaction

Mild, transient

—

Hematopoiesis

None — non-erythropoietic

Distinguishes ARA 290 from native EPO.

—

Cardiovascular

No thrombotic events or hypertension reported

—

Immunogenicity

No antibody formation reported

Unknown — no antibody development studies published

Tolerability

Well-tolerated in Phase 2 trialsCulver 2017 Brines 2015

—

Injection site reactions

—

Mild erythema, induration (presumed)

Systemic adverse events

—

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

Long-term safety

—

Unknown — no extended human trials indexed in PubMed

Absolute Contraindications

ARA 290

·Hypersensitivity to ARA 290

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

Relative Contraindications

ARA 290

·Active malignancy (theoretical EPO-axis concern; not observed in trials)

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

05Administration Protocol

Parameter

ARA 290

Cardiogen

1. Preparation

Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

3. Timing

Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015

Variable — often evening injection. No established circadian preference.

4. Dosing

4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

5. Storage

Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.

27–30G insulin syringe, 45° angle for subcutaneous administration.

06Stack Synergy

ARA 290

+ BPC-157

Moderate

View BPC-157 →

ARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.

ARA 290: 4 mg SQ · daily
BPC-157: 250–500 mcg SQ · daily
Frequency: Once daily, same or separate injections
Primary benefit: Nerve regeneration, pain reduction, tissue healing

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis